ORIGINAL RESEARCH
Reduced shedding and clinical signs of Salmonella Typhimurium
in nursery pigs vaccinated with a Salmonella Choleraesuis
vaccine
Samuel D. Charles, BVSc, MS, PhD, ACPV; Albert S. Abraham,
BVSc, PhD; Emilio T. Trigo, MVZ, MS, PhD; Gary F. Jones, DVM,
PhD, Terry L. Settje, BA
Charles SD, Abraham AS, Trigo ET, et al. Reduced shedding
and clinical signs of Salmonella Typhimurium in nursery
pigs vaccinated with a Salmonella Choleraesuis vaccine.
Swine Health Prod. 2000;8(3):107-112. This article
is also available in PDF format (464k).
SDC, ASA, ETT, TLS: Bayer Corporation, Agriculture Division,
Shawnee Mission, Kansas 66201; GFJ: presently at Schering Plough
Animal Health
Summary
Objective: To determine whether vaccination with a modified-live
Salmonella serotype Choleraesuis vaccine can protect pigs
3 weeks of age or older against infection caused by Salmonella
serotype Typhimurium.
Methods: Three studies were conducted using 3- to 4-week-old
crossbred pigs. The studies differed in the number of times the
vaccine was administered (twice in Study One, once in Studies
Two and Three), the severity of the challenge (1 x 1010
in Studies One and Two, 1 x 106 in Study Three), and
the principle variables recorded during the study (clinical disease
in Studies One and Two, shedding and isolation of the challenge
organism in feces and tissues in Studies One and Three). In each
study, pigs in a VACC-CHAL group were vaccinated orally (individually
in Study One or with a water proportioner in Studies Two and Three)
at 3 weeks of age and challenged 3 weeks later with virulent Salmonella
Typhimurium. CHAL pigs were challenged but not vaccinated,
and Control pigs were neither vaccinated nor challenged. Pigs
were weighed and their temperatures were taken; they were scored
for clinical signs of disease and for fecal consistency; and fecal,
serum, and necropsy samples were taken for culture and ELISA.
Results: A significant difference in average percent
healthy pigs, increased average daily gains, and lower rectal
temperatures were observed in the VACC-CHAL pigs compared to CHAL
pigs in Studies One and Two. Vaccinated pigs shed Salmonella
Typhimurium for significantly fewer days than the CHAL pigs,
and Salmonella Typhimurium was recovered from significantly
more tissues and in greater numbers from nonvaccinated pigs than
from the vaccinated pigs in Study Three.
Implications: A Salmonella Choleraesuis vaccine
can aid in preventing disease and reduce the shedding and colonization
of Salmonella Typhimurium in pigs >=3 weeks of age.
Keywords: swine, Salmonella,
vaccine, Salmonella serotype Typhimurium; Salmonella
serotype Choleraesuis
Received: December 7, 1999
Accepted: March 2, 2000
The two most common causes
of salmonellosis in swine are Salmonella serotype Choleraesuis
and Salmonella serotype Typhimurium.1 Salmonella
Typhimurium infections, most commonly seen in intensively
reared weaned pigs, cause an enterocolitis of variable severity,
followed by a carrier state that can last up to 28 weeks.1,2
Infected pigs are believed to be the primary source of infection
for other pigs and pork carcasses.
Efficacious modified-live (ML) vaccines for swine are commercially
available for Salmonella Choleraesuis but not for Salmonella
Typhimurium.3 Cross protection between Salmonella
serogroups has been demonstrated in poultry,4 but the
results of studies in other species have not been consistent.
In cattle, ML vaccines administered by intramuscular (IM)
injection have provided a degree of cross protection between Salmonella
Typhimurium and Salmonella serotype Dublin,5,6
and between Salmonella Choleraesuis and Salmonella Dublin.7
However, results of studies on the vaccination of cattle with
orally administered avirulent Salmonella Dublin have been
unable to demonstrate protection against Salmonella Typhimurium.8
We are unaware of any reports of studies of cross protection
between Salmonella Choleraesuis and Salmonella Typhimurium
in swine. The objective of this series of three consecutive studies
was to determine whether a commercially available ML [Delta]cya
[Delta](crp-cdt) Salmonella Choleraesuis vaccine (administered
either once or twice) could reduce the shedding of Salmonella
Typhimurium and the clinical signs of disease in 3- to 4-week-old
pigs after experimental challenge (at two different challenge
doses) with a wild strain of Salmonella Typhimurium.
Materials and methods
All three studies were performed consecutively with crossbred
3- to 4-week-old pigs obtained from a commercial farm negative
for fecal shedding of Salmonellae or serum antibodies to Salmonella
Choleraesuis outer membrane proteins (OMPs). In each study, the
pigs were weighed, ear tagged, and randomly allocated to one of
three separate isolation rooms at the Bayer Animal Research Facility
in Rushmore, Minnesota. After a 4-day acclimation period, each
roomful of pigs was assigned to one of three treatment groups:
- "VACC-CHAL,"
- "CHAL," or
- "Control."
The "VACC-CHAL" group was vaccinated:
- twice (2 weeks apart) in Study One (VACC-CHAL1) individually
per os, or
- once in Studies Two and Three (VACC-CHAL2 and VACC-CHAL3)
by water proportioner
with a ML [Delta]cya [Delta](crp-cdt) Salmonella Choleraesuis
vaccine (Argus(TM) SC, Bayer Corporation; Shawnee Mission, Kansas)
(Table 1). To prepare vaccine, 1
mL of sterile diluent-hydrated vaccine was suspended into 9 mL
of water according to the insert and label directions. Water was
withheld for 6 hours prior to vaccine administration.
Approximately 3 weeks after vaccination, each pig in the VACC-CHAL
group was restrained and orally given 10 mL of the adjusted challenge
culture Salmonella Typhimurium (P93-482) using a
plastic syringe, at:
- 1x1010 colony forming units (CFU) for Studies
One and Two, and
- 1x106 CFU for Study Three (Table
1).
The "CHAL" (CHAL1, CHAL2, and CHAL3) group received
the Salmonella Typhimurium challenge on the same day of
the study as the VACC-CHAL pigs received their challenge, but
no vaccine.
The "Control" (Control1, Control2, Control3) group
received neither vaccine nor challenge.
To prepare the challenge dose, a frozen vial of the challenge
strain was thawed in a 98.6 degrees F (37 degrees C) water bath.
One mL of the thawed culture was transferred to a 2-L Erlenmeyer
flask which contained 500 mL of MLB (Modified Luria Bertani).
After overnight incubation of static growth at 37 degrees C +/-
2 degrees C (98.6 degrees F +/- 3.6 degrees F), aliquots of this
culture were adjusted with sterile saline solution to the desired
concentration, and stored in an icewater bath until administered
to the pigs.
Feed was withheld from the pigs for 18 hours prior to challenge
and returned to the pigs 30 minutes after challenge-exposure in
each of the studies.
Sampling and data collection
During the prevaccination acclimation period, normal "baseline"
scores for physical condition and fecal consistency were made
for each pig. Fecal consistency and physical condition were evaluated
daily after challenge for each pig on a scale of 1 (normal) to
4 (most severe). In addition, fecal and serum samples were collected
and evaluated by culture and ELISA to determine whether the pigs
were free of Salmonella.
Pigs were individually weighed three times: prior to vaccination,
prior to challenge, and prior to necropsy, and the average daily
gain (ADG) for the postchallenge period was calculated.
Physical condition scores and fecal consistency scores were
recorded daily starting 2 days before challenge through day 10
postchallenge, and on days 12-14 postchallenge for each animal.
The rectal temperature of each pig was recorded daily after
challenge, and the maximum and mean rectal temperatures were determined.
The maximum rise in temperature for each pig was calculated as
the difference between the maximum postchallenge and the mean
prechallenge normal rectal temperatures.
Fecal samples were collected daily (in Studies One and Three
only) for culture (Table 1). In addition,
approximately 1 g each of liver, spleen, ileo-cecal junction (ICJ),
tonsils, and mesenteric lymph node (MLN) were collected at necropsy.
Blood samples were collected postvaccination and postchallenge.
Sera were stored at -20 degrees C until tested for antibodies
to Salmonella Choleraesuis (prevaccination and postvaccination)
and Salmonella Typhimurium (postchallenge) OMPs using an
enzyme-linked-immunosorbent-assay (ELISA).
Mortality was recorded throughout each study.
Culture
Aliquots of fecal samples and homogenized tissues were plated
onto brilliant green agar plates (BGA), both directly (after serial
dilution with phosphate-buffered saline) and after enrichment
in Rappaport-Vassiliadis Broth (Difco; Detroit, Michigan) at 37°C
+/- 0.55°C (98.6 degrees F +/- 1 degrees F) for 18-24 hours.
Plates were incubated at 37°C +/- 0.55°C (98.6 degrees
F +/- 1 degrees F) for 24 and 48 hours and examined for pink colonies
typical of Salmonella spp. Presumptive identification
was based on standard biochemical tests and slide agglutination
with Salmonella 'O' Group B antisera (Difco).
Serology
Sarkosyl-insoluble OMPs were isolated and dissolved in phosphate-buffered
saline (PBS, pH 7.2), diluted in sodium bicarbonate buffer, and
used to coat plate wells. The coated wells were incubated overnight
at 4 degrees C, washed with PBS-Tween 20 (0.05%), and blocked
with PBS-bovine serum albumin (BSA, 0.05%). Aliquots (100 µL)
of serially diluted (1:100-1:3200) serum samples were added to
the OMP-coated wells, in duplicate. After 1 hour of incubation
at room temperature, the wells were washed four times with PBS-Tween
20. Aliquots (100 µL) of a solution of horseradish peroxidase-labeled
anti-swine IgG in PBS-BSA were added to the wells. The plates
were incubated for 1 hour at room temperature after which the
wells were washed four times with PBS-Tween 20. Aliquots (100
µL) of a solution of ABTS-hydrogen sulfide (substrate) were
added to the wells and the plates were incubated at room temperature
for 30 minutes. An aliquot (50 µL) of 2% sodium dodecyl
sulphate (SDS) solution was added to each well after which the
optical density (OD) of each well was read at 405 nm wavelength.
The OD of the blank wells was subtracted from the OD from each
of the test wells.
Statistical analysis
The number of days a pig was recorded with a fecal score of
1 were proportionalized by dividing with the total number of observation
days postchallenge. This proportion is referred to as the percent
"normal" days per pig. Similarly for the physical condition
scores, a percent "healthy" days per pig variable was
determined from pigs that received a score of 1 and proportionalized
by dividing with the total number of postchallenge observation
days.
Also, the number of days a pig was shown shedding Salmonella
was proportionalized by dividing with the total number of
days the pig was culture-tested postchallenge. This proportion
is referred to as the percent shedding days. Second, the number
of pigs per day that Salmonella was isolated from the feces
was also determined and proportionalized by dividing with the
total number of pigs per group per day. This proportion is referred
to as the percent animals shedding per day.
Variables derived from fecal scores; physical scores; fecal
shedding; average daily gains; maximum, mean, and maximum rise
in body temperatures; and percent tissues positive were analyzed
using ANOVA, testing for group effects, provided tests for normality
and homogeneity of variances were met. Wilcoxon's rank sum test
was applied where criteria for ANOVA were not met. Similarly,
rectal temperatures recorded postchallenge were also analyzed
using repeated-measures ANOVA.
Results
The Control pigs (Control1, Control2, and Control3) remained
clinically normal in all studies. Salmonella Typhimurium
was isolated once from the tonsils and feces of one Control1 and
one Control3 pig. However, no Salmonellae were isolated from the
feces or tissues of Control2 pigs.
There was no significant increase in the postvaccination antibody
titers of the VACC-CHAL pigs in any of the three studies. CHAL1
and CHAL2 pigs developed clinical signs of salmonellosis (inappettance,
lethargy, and/or gauntness with or without rough hair coat), and
in all studies Salmonella Typhimurium was detected in the
feces of all CHAL pigs, demonstrating that Salmonella Typhimurium
infection was established in the pigs that were challenged.
Study One
The VACC-CHAL1 and CHAL1 pigs had group mean body temperatures
above 40°C (104 degrees F) only during the first 3 days after
challenge. The mean body temperature of the VACC-CHAL1 pigs on
days 2 and 3 postchallenge were significantly (P<.05)
lower than those of the CHAL1 pigs, (Figure
1).
VACC-CHAL1 pigs had a significantly (P<.05) greater
percent of healthy pigs per day after challenge than did the CHAL1
pigs (Figure 2). Also, the percent
of VACC-CHAL1 pigs with normal fecal scores was significantly
(P<.05) greater than the CHAL1 pigs (Figure
3). The ADG of the VACC-CHAL1 pigs was significantly (P<.05)
greater than that of the CHAL1 pigs (Figure
4).
Although there was no statistical difference between the two
groups in the number of pigs that shed Salmonella Typhimurium
or had Salmonella Typhimurium in their tissues, VACC-CHAL1
pigs had fewer Salmonella Typhimurium in their tissues
than the CHAL1 pigs (Figure 5).
Study Two
Four pigs died after challenge, three in the CHAL2 group and
one in the VACC-CHAL2 group.
Body temperatures in both the VACC-CHAL2 and CHAL2 pigs were
elevated above normal values 24 hours after challenge with virulent
Salmonella Typhimurium (Figure
1). The mean body temperature of the VACC-CHAL2 pigs returned
to normal within 48 hours after challenge, but that of the CHAL
pigs remained above normal. On days 2, 3, and 4 postchallenge,
the mean body temperatures of the VACC-CHAL2 pigs were significantly
lower (P<.05) than those of the CHAL2 pigs. Mean rectal
temperatures, maximum rectal temperatures, and the rise in rectal
temperatures did not differ significantly between the VACC-CHAL2
and the nonvaccinated groups postchallenge.
The average percent of healthy pigs was significantly greater
(P<.05) in the VACC-CHAL2 group than in the CHAL2 group
(Figure 2). The average percent of
vaccinated pigs with normal fecal scores was significantly (P<.05)
greater than in the CHAL2 group (Figure
3). The average daily gain of the VACC-CHAL2 pigs was significantly
(P<.05) greater than that of the CHAL2 pigs (Figure
4).
Study Three
Pigs developed only mild and transient clinical signs of disease
in Study Three (Figure 2). As a result,
group differences in average daily gain, body temperature, and
clinical signs were not significant in Study Three.
Significantly more CHAL3 pigs (15 of 19) than VACC-CHAL3 pigs
(two of 21) were culture-positive for Salmonella Typhimurium
in at least one tissue (P<.01) at necropsy (Figure
5). Salmonella Typhimurium was isolated from a significantly
greater proportion of tissues from the CHAL3 pigs than from the
VACC-CHAL3 pigs (10.0%, P<.05). A higher percent of
CHAL3 pigs were positive with the challenge organism in tonsils,
ICJ and MLN when compared with the VACC-CHAL3 pigs.
The CHAL3 pigs were detected shedding Salmonella Typhimurium
significantly (P<.05) more days than the vaccinated
pigs postchallenge. A significant (P<.01) number of
CHAL3 pigs (11) were detected shedding Salmonella Typhimurium
in feces than the vaccinates (zero) on the last day of the observation
period (Figure 6). None of the vaccinated
pigs shed Salmonella Typhimurium in feces beyond day 9
postchallenge, while 11 of the 19 CHAL3 pigs were still shedding
Salmonella Typhimurium in feces on day 14. The mean number
of Salmonella Typhimurium in the feces of the CHAL3 pigs
(7.5 per g) was significantly greater (P<.05) than the
number in the VACC-CHAL3 pigs (0 per g) on day 7 postchallenge,
and was higher on day 9 postchallenge (2.5 per g versus 0 per
g) (Figure 7).
Discussion
The clinical signs, body temperature, and culture results in
the respective vaccinated pigs of studies One and Two were similar
to other reports of experimental Salmonella Typhimurium
infection of weaned pigs challenged with approximately the same
dose of virulent bacteria.2,10 In those studies, as
in these, the mean rectal temperatures peaked in the first 2 days
postchallenge and were elevated until day 4 or later, diarrhea
was seen in 80%-90% of the nonvaccinated challenged pigs, and
clinical signs varied from mild to severe.
Isolation of Salmonella Typhimurium in Study Three was
primarily from the tonsils, ICJ, and MLN of the nonvaccinated
pigs. This is consistent with the previous studies in which deep
tissues (liver and spleen) were rarely infected, but mucosal and
lymphoid tissues were commonly infected.2,10 The serological
data (data not shown) indicated that the immunoglobulin- (IgG-)
mediated response to the Salmonella Choleraesuis OMP
antigens, induced by the vaccine delivered orally, was minimal
and did not differ significantly from that of the unvaccinated
animals. This may explain the lack of humoral response to either
vaccination or infection in the vaccinated and nonvaccinated pigs,
as the immunity at the mucosal level is largely mediated by secretory
immunoglobulin A and cell-mediated immunity.11
The differences between the clinical signs of disease seen
in vaccinates and nonvaccinates in studies One and Two were similar
to those described in a report of an experimental [Delta]cya [Delta](crp-cdt)
Salmonella Typhimurium vaccine.10 The gene deletions
in that vaccine are also among the deletions [[Delta]cya [Delta](crp-cdt)]
present in the Salmonella Choleraesuis vaccine used in
these studies. In that report, as in these studies, the mean body
temperatures of vaccinated pigs returned to normal by 48 hours
after challenge, and significantly fewer (50%) of the vaccinated
pigs than nonvaccinates (90%) developed diarrhea. The vaccinated
pigs in that study were lethargic and demonstrated a depressed
appetite, but returned to normal by 48 hours after challenge,
while similar measures of the nonvaccinated pigs were more severe
and required longer to return to normal.
Studies in cattle with oral vaccination with [Delta]aro A [Delta]aro
D Salmonella Dublin vaccines did not demonstrate cross
protection between Salmonella Typhimurium and Salmonella
Dublin.8,9 The attenuating mutations in those vaccines
severely limit the growth of the bacteria in mammalian tissues,
and Salmonella Choleraesuis is genetically more similar
to both Salmonella Typhimurium and Salmonella Dublin
than either is to each other.12 The host species difference,
the difference in the attenuating mutation, or the difference
in serovars used may all be responsible for the disparate results.
Although Salmonella spp. may survive for long periods
in the environment, it is widely believed that the carrier animal
is the major source of infections for both animals and humans.1
The significant reduction in shedding of Salmonella Typhimurium,
and the lower prevalence of the challenged organism in the tissues
suggests that vaccination with the [Delta]cya [Delta](crp-cdt)
Salmonella Choleraesuis vaccine would be a useful tool
in preventing salmonellosis in swine.
Implications
- A commercially available [Delta]cya [Delta](crp-cdt) Salmonella
Choleraesuis modified-live vaccine administered as per the
label directions can aid in reducing shedding and clinical signs
of Salmonella Typhimurium in pigs >= 3 weeks of age.
- A significant degree of cross protection between the Salmonella
Choleraesuis vaccine and Salmonella Typhimurium has
been demonstrated.
References
1. Schwartrz KJ. Salmonellosis. In: Straw BE, Mengeling
WL, D'Allaire S, Taylor DJ, eds. Diseases of Swine, 8th
ed. Ames, Iowa: Iowa State University Press. 1999; 535-551.
2. Wood RL, Rose R. Populations of Salmonella Typhimurium
in internal organs of experimentally infected carrier swine. Am
J Vet Res. 1992; 53:653-658.
3. Kelly SM, Bosecker BA, Curtiss III R. Characterization and
protective properties of attenuated mutants of Salmonella choleraesuis.
Infect Immun. 1992; 60:4881-4890.
4. Charles SD, Nagaraja KV, Sivanandan V. A lipid-conjugated
immunostimulating complex subunit vaccine against Salmonella
infection in turkeys. Avian Dis. 1992; 37:477-484.
5. Smith BP, Reina-Guerra M, Stocker BAD, et al. Vaccination
of calves against Salmonella dublin with aromatic-dependent
Salmonella typhimuirum. Am J Vet Res. 1984; 45:1858-1861.
6. Smith BP, Reina-Guerra M, Stocker BAD, et al. Aromatic-dependent
Salmonella dublin as a parenteral modified live vaccine
for calves. Am J Vet Res. 1984; 45:2231-2235.
7. Bryce CF, Fox BC, Roof MB, Carter DP, et al. Safety and
efficacy of an avirulent live Salmonella choleraesuis vaccine
for protection of calves against S dublin infection. Am
J Vet Res. 1997; 58:265-271.
8. Segall T, Lindberg AA. Oral Vaccination of calves with an
aromatic-dependent Salmonella dublin (09,12) hybrid expressing
O4, 12 protects against S. dublin (09,12) but not against
Salmonella typhimurium (04,5,12). Infect Immun.
1993; 61:1222-1231.
10. Coe NE, Wood RL. The effect of exposure to a cya/crp mutant
of Salmonella typhimurium on the subsequent colonization
of swine by the wild-type parent strain. Vet Micro. 1992;
31:207-220.
11. Brandtzaeg P, Baekkevold ES, Farstad IN, et al. Regional
specialization in the mucosal immune system: What happens in the
microcompartments? Immun Today. 1990; 20:141-151.
12. Chu C, Hong S-F, Tsai C, et al. Comparative physical and
genetic maps of the virulence plasmids of Salmonella enterica
serovars Typhimurium, Enteriditis, Choleraesuis, and Dublin.
Infect Immun. 1990; 67:2611-2614.
References-nonrefereed
9. Villarreal B, Paulin SM, Watson PR, et al. Analysis of the
specificity of protection induced by Salmonella s in cattle.
Proc Salmonella and Salmonellosis; Ploufragen, France,
1997.
|